Kwality Pharmaceuticals Posts Robust Q2 FY27 Growth and Appoints BSR as Auditor
Kwality Pharmaceuticals Ltd · Change in Auditor · 12 Nov 2026, 6:35 pm
Kwality Pharmaceuticals Posts Robust Q2 FY27 Growth and Appoints BSR as Auditor Kwality Pharmaceuticals reported strong Q2 FY27 results, with consolidated revenue surging 63% YoY to ₹181 crore and PAT doubling YoY to ₹50 crore. EBITDA margin expanded to 27.5% from 23.4% in Q2 FY26. Consequently, management raised its FY27 revenue guidance to ₹720+ crore from ₹700 crore. Additionally, the company acquired 4 acres in Amritsar for Unit 7, secured Hungarian EU-GMP certification, and appointed B S R & Co. LLP as statutory auditor on 12th Nov'26 to fill the casual vacancy following Vijay Mehra & Co.'s resignation.
Original exchange filing (PDF)
More announcements from Kwality Pharmaceuticals Ltd
- Transcript of Earnings Conference Call - Q2FY2027 · 16 Nov 2026
- Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Recording of Investor/ Analyst Earnings Call held on November 13, 2026 · 14 Nov 2026
- Intimation under Regulation 30 of the SEBI(LODR), 2015 -Recording of Investor/ Analyst Earnings Call held on September 13, 2026 · 14 Nov 2026
- Investor Presentation for the quarter and half year ended unaudited financial results for 30-09-2026 · 12 Nov 2026
- Appointment of new Statutory Auditors · 12 Nov 2026
- Approval of Unaudited Financial Results for the quarter and half year ended 30-09-2026. · 12 Nov 2026
- Approval of Unaudited Financial Results for the quarter and half year ended 30-09-2026 · 12 Nov 2026
- Intimation of Earnings Conference Call for Q2 FY 2026-27 & REVISED LINK FOR REGISTRATION · 13 Nov 2026
